Literature DB >> 29064467

Parkinson disease: Caffeine and nicotine do not provide symptomatic relief in Parkinson disease.

Heather Wood.   

Abstract

Entities:  

Year:  2017        PMID： 29064467     DOI： 10.1038/nrneurol.2017.155

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  2 in total

1.  High-dose transdermal nicotine in Parkinson's disease patients: a randomized, open-label, blinded-endpoint evaluation phase 2 study.

Authors:  G Villafane; C Thiriez; E Audureau; C Straczek; P Kerschen; F Cormier-Dequaire; A Van Der Gucht; J-M Gurruchaga; M Quéré-Carne; E Evangelista; M Paul; G Defer; P Damier; P Remy; E Itti; G Fénelon
Journal:  Eur J Neurol       Date:  2017-10-23       Impact factor: 6.089

2.  Caffeine as symptomatic treatment for Parkinson disease (Café-PD): A randomized trial.

Authors:  Ronald B Postuma; Julius Anang; Amelie Pelletier; Lawrence Joseph; Mariana Moscovich; David Grimes; Sarah Furtado; Renato P Munhoz; Silke Appel-Cresswell; Adriana Moro; Andrew Borys; Douglas Hobson; Anthony E Lang
Journal:  Neurology       Date:  2017-09-27       Impact factor: 9.910
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.